Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 30, 2020 - Issue 5
Submit an article Journal homepage
664
Views
17
CrossRef citations to date
0
Altmetric
Review

Tropomyosin receptor kinase inhibitors: an updated patent review for 2016–2019

Justin J. BaileyDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, CanadaCorrespondence[email protected]
View further author information
,
Carolin JaworskiDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, CanadaView further author information
,
Donovan TungDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, CanadaView further author information
,
Carmen WänglerBiomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, GermanyView further author information
,
Björn WänglerMolecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, GermanyView further author information
&
Ralf SchirrmacherDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, CanadaView further author information
Pages 325-339 | Received 24 Jan 2020, Accepted 27 Feb 2020, Published online: 10 Mar 2020

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Carolin Jaworski, Petar Iliev, Carmen Wängler, Björn Wängler, Brent Page, Ralf Schirrmacher & Justin J. Bailey. (2023) Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update. Expert Opinion on Therapeutic Patents 33:7-8, pages 503-521.
Read now

Articles from other publishers (16)

Hala B. El-Nassan & Mustafa A. Al-Qadhi. (2023) Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review. European Journal of Medicinal Chemistry 258, pages 115618.
Crossref
Mohammad Malekan, Sasan Salehi Nezamabadi, Elham Samami, Mehdi Mohebalizadeh, Amene Saghazadeh & Nima Rezaei. (2022) BDNF and its signaling in cancer. Journal of Cancer Research and Clinical Oncology 149:6, pages 2621-2636.
Crossref
Giampiero Ferraguti, Sergio Terracina, Ginevra Micangeli, Marco Lucarelli, Luigi Tarani, Mauro Ceccanti, Matteo Spaziani, Valerio D’Orazi, Carla Petrella & Marco Fiore. (2023) NGF and BDNF in pediatrics syndromes. Neuroscience & Biobehavioral Reviews 145, pages 105015.
Crossref
Christine Martineau, Maria-Kim Turcotte, Noémie Otis, Frédéric Provost, Ludovic Themens, Marie-Pascale Guay, Nathalie Letarte & Jean-Philippe Adam. (2022) Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review. Supportive Care in Cancer 30:12, pages 10471-10482.
Crossref
Kun Pang, Wei Wang, Jia‐Xin Qin, Zhen‐Duo Shi, Lin Hao, Yu‐Yang Ma, Hao Xu, Zhuo‐Xun Wu, Deng Pan, Zhe‐Sheng Chen & Cong‐Hui Han. (2022) Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. MedComm 3:4.
Crossref
Yi Gong, Feng-Xu Wu, Ming-Shu Wang, Hong-Chuang Xu, Lin-Sheng Zhuo, Guang-Fu Yang & Wei Huang. (2022) Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance. European Journal of Medicinal Chemistry 241, pages 114654.
Crossref
Zhijie Wang, Jiwei Ren, Kun Jia, Yuming Zhao, Li Liang, Zitian Cheng, Fei Huang, Xiaofei Zhao, Jie Cheng, Shiyu Song, Tiancheng Sheng, Weiqi Wan, Qingqing Shu, Donglin Wu, Junhao Zhang, Tao Lu, Yadong Chen, Ting Ran & Shuai Lu. (2022) Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor. European Journal of Medicinal Chemistry 241, pages 114601.
Crossref
Alberto Ricci, Claudia Salvucci, Silvia Castelli, Antonella Carraturo, Claudia de Vitis & Michela D’Ascanio. (2022) Adenocarcinomas of the Lung and Neurotrophin System: A Review. Biomedicines 10:10, pages 2531.
Crossref
Jie Wang, Yang Zhou, Xia Tang, Xiuwen Yu, Yongjin Wang, Shingpan Chan, Xiaojuan Song, Zhengchao Tu, Zhimin Zhang, Xiaoyun Lu, Zhang Zhang & Ke Ding. (2022) JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo. Molecules 27:19, pages 6500.
Crossref
Toshiya Ito, Kazutomo Kinoshita, Masaki Tomizawa, Shojiro Shinohara, Hiroki Nishii, Masayuki Matsushita, Kazuo Hattori, Yasunori Kohchi, Masami Kohchi, Tadakatsu Hayase, Fumio Watanabe, Kiyoshi Hasegawa, Hiroshi Tanaka, Shino Kuramoto, Kenji Takanashi & Nobuhiro Oikawa. (2022) Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor. Journal of Medicinal Chemistry 65:18, pages 12427-12444.
Crossref
J.P.M. Vrouwe, J. Burggraaf, M. Kloppenburg & F.E. Stuurman. (2021) Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments. Osteoarthritis and Cartilage Open 3:4, pages 100212.
Crossref
Mu-Chun Li, Wen-Hsing Lin, Pei-Chen Wang, Yu-Chieh Su, Pei-Yi Chen, Chu-Min Fan, Ching-Ping Chen, Chen-Lung Huang, Chun-Hsien Chiu, Ling Chang, Chiung-Tong Chen, Teng-Kuang Yeh & Hsing-Pang Hsieh. (2021) Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization. European Journal of Medicinal Chemistry 224, pages 113673.
Crossref
Tingting Jiang, Guan Wang, Yao Liu, Lu Feng, Meng Wang, Jie Liu, Yi Chen & Liang Ouyang. (2021) Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharmaceutica Sinica B 11:2, pages 355-372.
Crossref
Mu‐Chun Li & Hsing‐Pang Hsieh. (2020) Tumor‐agnostic inhibitors in oncology: A new phase for precision medicine . Journal of the Chinese Chemical Society.
Crossref
Yuekun Wang, Piaopiao Long, Yu Wang & Wenbin Ma. (2020) NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma. Frontiers in Oncology 10.
Crossref
Yunxin Duan, Jie Wang, Sihua Zhu, Zheng-Chao Tu, Zhang Zhang, Shingpan Chan & Ke Ding. (2020) Design, synthesis, and Structure–Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors. European Journal of Medicinal Chemistry 203, pages 112552.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.